Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
Press releases
-
AlzeCure enters the next development phase with ACD857 for Alzheimer’s disease
December 14, 2020
-
AlzeCure presents positive preclinical efficacy data for the TrkA-NAM pain project
December 9, 2020
-
AlzeCure receives approval to start clinical Phase Ib trial with ACD440 in neuropathic pain
December 7, 2020